Kyrgyzstan vs United States: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Kyrgyzstan
84.0%
in 2025
United States
84.0%
in 2025
Kyrgyzstan rank
102nd
United States rank
102nd
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Kyrgyzstan
- United States
How they compare
Kyrgyzstan currently reports 84.0% against 84.0% in United States, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was United States ahead.
Kyrgyzstan ranks 102nd and United States ranks 102nd of 194 countries.
Across the 3 decades both report, Kyrgyzstan averaged higher in 1 and United States in 2.
Head to head by decade
| Decade | Kyrgyzstan | United States | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 93.0% | 93.0% | United States |
| 2010s | 27.6% | 92.6% | 65.0% | United States |
| 2020s | 88.8% | 83.3% | 5.5% | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Kyrgyzstan or United States?
- Kyrgyzstan, at 84.0% against 84.0% in United States as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Kyrgyzstan and United States?
- 0.0%, with Kyrgyzstan ahead.
- How many years of comparable data are there for Kyrgyzstan and United States?
- 18 years are reported by both, from 2008 to 2025.
- How do Kyrgyzstan and United States rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Kyrgyzstan ranks 102nd and United States ranks 102nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.